Histone Deacetylase 3 (SMAP45 or EC 3.5.1.98) - Pipeline Review, H1 2016 - Product Image

Histone Deacetylase 3 (SMAP45 or EC 3.5.1.98) - Pipeline Review, H1 2016

  • ID: 3788888
  • Report
  • 81 pages
  • Global Markets Direct
1 of 6

FEATURED COMPANIES

  • 4SC AG
  • Curis, Inc.
  • GlaxoSmithKline Plc
  • HitGen LTD
  • IRBM Science Park SpA
  • Merck & Co., Inc.
  • MORE
Histone Deacetylase 3 (SMAP45 or EC 3.5.1.98) - Pipeline Review, H1 2016

Summary

‘Histone Deacetylase 3 (SMAP45 or EC 3.5.1.98) - Pipeline Review, H1 2016’, provides in depth analysis on Histone Deacetylase 3 (SMAP45 or EC 3.5.1.98) targeted pipeline therapeutics.

The report provides comprehensive information on the Histone Deacetylase 3 (SMAP45 or EC 3.5.1.98), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Histone Deacetylase 3 (SMAP45 or EC 3.5.1.98) targeted therapeutics development and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Histone Deacetylase 3 (SMAP45 or EC 3.5.1.98)
- The report reviews Histone Deacetylase 3 (SMAP45 or EC 3.5.1.98) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Histone Deacetylase 3 (SMAP45 or EC 3.5.1.98) targeted therapeutics and enlists all their major and minor projects
- The report assesses Histone Deacetylase 3 (SMAP45 or EC 3.5.1.98) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Histone Deacetylase 3 (SMAP45 or EC 3.5.1.98) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Histone Deacetylase 3 (SMAP45 or EC 3.5.1.98)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Histone Deacetylase 3 (SMAP45 or EC 3.5.1.98) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • 4SC AG
  • Curis, Inc.
  • GlaxoSmithKline Plc
  • HitGen LTD
  • IRBM Science Park SpA
  • Merck & Co., Inc.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Histone Deacetylase 3 (SMAP45 or EC 3.5.1.98) Overview

Therapeutics Development

Histone Deacetylase 3 (SMAP45 or EC 3.5.1.98) - Products under Development by Stage of Development

Histone Deacetylase 3 (SMAP45 or EC 3.5.1.98) - Products under Development by Therapy Area

Histone Deacetylase 3 (SMAP45 or EC 3.5.1.98) - Products under Development by Indication

Histone Deacetylase 3 (SMAP45 or EC 3.5.1.98) - Pipeline Products Glance

Late Stage Products

Early Stage Products

Histone Deacetylase 3 (SMAP45 or EC 3.5.1.98) - Products under Development by Companies

Histone Deacetylase 3 (SMAP45 or EC 3.5.1.98) - Products under Development by Universities/Institutes

Histone Deacetylase 3 (SMAP45 or EC 3.5.1.98) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Histone Deacetylase 3 (SMAP45 or EC 3.5.1.98) - Companies Involved in Therapeutics Development

4SC AG

Chipscreen Biosciences Ltd

Curis, Inc.

GlaxoSmithKline Plc

HitGen LTD

IRBM Science Park SpA

Merck & Co., Inc.

Sigma-Tau S.p.A.

Syndax Pharmaceuticals, Inc.

TetraLogic Pharmaceuticals

Histone Deacetylase 3 (SMAP45 or EC 3.5.1.98) - Drug Profiles

4SC-202 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

chidamide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CUDC-907 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug to Inhibit HDAC-3 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

entinostat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HG-3001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Largazole - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

N-140 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

remetinostat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit HDAC1, HDAC3 and HDAC6 for Lung Adenocarcinoma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Histone Deacetylases for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ST-3595 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vorinostat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Histone Deacetylase 3 (SMAP45 or EC 3.5.1.98) - Dormant Projects

Histone Deacetylase 3 (SMAP45 or EC 3.5.1.98) - Featured News & Press Releases

Jun 08, 2016: Curis Announces Oral Presentation of Clinical Data Update from the Phase 1 Study of CUDC-907 at the 21st Congress of the European Hematology Association

Jun 02, 2016: Curis Announces Presentations Related to CUDC-907 at 2016 ASCO Annual Meeting

May 18, 2016: Entinostat Data to be Highlighted at the American Society of Clinical Oncology 2016 Annual Meeting

Apr 11, 2016: Syndax Announces Entinostat Data to be Presented at the American Association for Cancer Research (AACR) 2016 Annual Meeting

Apr 11, 2016: Curis Announces Presentation of Preclinical Data for CUDC-907 at AACR Annual Meeting

Apr 04, 2016: Curis Announces Publication of CUDC-907 Phase 1 Clinical Trial Data in Lancet Oncology

Mar 21, 2016: Epigenetic compound 4SC-202 strengthens endogenous immune response to cancer

Mar 03, 2016: HUYA Bioscience International Expands Senior Management Team

Dec 22, 2015: Huya Bioscience International Announces Orphan Drug Designation For HBI-8000 In Japan

Dec 06, 2015: Curis Reports Clinical Activity of CUDC-907 in Patients With DLBCL Harboring MYC Oncogene Alterations at the 2015 ASH Annual Meeting

Dec 03, 2015: Syndax Announces Multiple Data Presentations on Entinostat at Upcoming San Antonio Breast Cancer Symposium

Dec 01, 2015: Syndax Announces Initiation Of Entinostat Clinical Program In Japan By Partner Kyowa Hakko Kirin

Nov 05, 2015: Curis Announces Oral Presentation of Phase 1 Data for CUDC-907 at 2015 ASH Annual Meeting

Nov 02, 2015: TetraLogic Announces the Opening of an IND for SHAPE Gel in Alopecia Areata

Sep 30, 2015: 4SC receives funding from the Eurostars programme for further research of its anti-cancer agent 4SC-202 with an epigenetic mode of action

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer 81List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Number of Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016 (Contd..1)

Products under Development by Companies, H1 2016 (Contd..2)

Number of Products under Investigation by Universities/Institutes, H1 2016

Products under Investigation by Universities/Institutes, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pipeline by 4SC AG, H1 2016

Pipeline by Chipscreen Biosciences Ltd, H1 2016

Pipeline by Curis, Inc., H1 2016

Pipeline by GlaxoSmithKline Plc, H1 2016

Pipeline by HitGen LTD, H1 2016

Pipeline by IRBM Science Park SpA, H1 2016

Pipeline by Merck & Co., Inc., H1 2016

Pipeline by Sigma-Tau S.p.A., H1 2016

Pipeline by Syndax Pharmaceuticals, Inc., H1 2016

Pipeline by TetraLogic Pharmaceuticals, H1 2016

Dormant Projects, H1 2016

Dormant Projects (Contd..1), H1 2016

Dormant Projects (Contd..2), H1 2016 68List of Figures

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Top 10 Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • 4SC AG
  • Curis, Inc.
  • GlaxoSmithKline Plc
  • HitGen LTD
  • IRBM Science Park SpA
  • Merck & Co., Inc.
  • MORE
Histone Deacetylase 3 (SMAP45 or EC 3.5.1.98) Histone deacetylase 3 is an enzyme encoded by the HDAC3 gene. Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Histone deacetylases act via the formation of large multiprotein complexes. It participates in the regulation of transcription through its binding with the zinc-finger transcription factor YY1. This protein can also down-regulate p53 function and thus modulate cell growth and apoptosis.

Histone Deacetylase 3 (SMAP45 or EC 3.5.1.98) pipeline Target constitutes close to 13 molecules. Out of which approximately 12 molecules are developed by Companies and remaining by the Universities/Institutes. The molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 2, 1, 3 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Our latest report Histone Deacetylase 3 – Pipeline Review, H1 2016, outlays comprehensive information on the Histone Deacetylase 3 (SMAP45 or EC 3.5.1.98) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Histone Deacetylase 3 (SMAP45 or EC 3.5.1.98) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases.

The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 6
4SC AG
Chipscreen Biosciences Ltd
Curis, Inc.
GlaxoSmithKline Plc
HitGen LTD
IRBM Science Park SpA
Merck & Co., Inc.
Sigma-Tau S.p.A.
Syndax Pharmaceuticals, Inc.
TetraLogic Pharmaceuticals
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll